Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days
Brief Summary: This is a multicenter, randomized study. 564 healthy women, age 18 years or older, with an intrauterine pregnancy, and requesting a medical abortion, will be recruited to participate in this prospective clinical trial. This study will provide an evaluation of oral mifepristone 200 mg and vaginal misoprostol 800 mcg administered simultaneously in women up to 63 days gestation. The aims of the study are to compare the complete abortion rates, at 7 and 14 days after misoprostol administration, when using mifepristone 200 mg orally and misoprostol 800 mcg vaginally are administered simultaneously and 24 hours apart in women up to 63 days gestation. Assessment of side effects (nausea, vomiting, pain) as well as acceptability will be done using pre and post-study questionnaires, and visual analogue scales. Complete abortion rate within 24 hours is expected to be 90%


Options:
A: Inclusion Criteria:

* Have an intrauterine pregnancy consistent with gestational age less than 71 days;
* Be able to understand and willing to sign a consent form;
* Be eligible for medical abortion according to the clinician's assessment;
* Be able to return to the clinic and able to contact study staff or emergency medical services, if needed;
* Be willing to provide an address and/or telephone number for purposes of follow-up;
* Agree to comply with the study procedures and visit schedule.

Exclusion Criteria:

* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;
* Chronic renal failure;
* Concurrent long-term corticosteroid therapy;
* History of allergy to mifepristone, or misoprostol or another prostaglandin;
* History of hemorrhagic disorders or concurrent anticoagulant therapy;
* History of inherited porphyrias;
* Intrauterine device in place (must be removed before mifepristone is administered).
B: Inclusion Criteria:

* Be willing and able to sign consent forms;
* Be eligible for menstrual regulation (MR) services according to clinician's assessment;
* Be willing to undergo a surgical evacuation if necessary;
* Be willing to provide a urine sample prior to administration of the mifepristone
* Have ready and easy access to a telephone and
* Agree to comply with the study procedures and visit schedule

Exclusion Criteria:

* • Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;

  * Chronic renal failure;
  * Concurrent long-term corticosteroid therapy;
  * History of allergy to mifepristone, misoprostol or other prostaglandin;
  * Hemorrhagic disorders or concurrent anticoagulant therapy;
  * Inherited porphyrias; or
  * Other serious physical or mental health conditions.
C: Inclusion Criteria:

* Reproductive age women seeking abortion services.
* Eligible women will be in general good health and assessed by a clinician to have an intrauterine pregnancy less than 64 days L.M.P on the day mifepristone will be taken.
* Participants must be eligible for medical abortion according to clinician and clinic standards.
* In the United States, women only 18 years and older will be eligible to participate, unless the study site obtains a waiver to include minors.
D: Inclusion Criteria:pregnancy equal to or less than 63 days at enrollment -

Exclusion Criteria:abnormal pregnancy diagnosed by ultrasound

-

Answer: D